Literature DB >> 22013127

The antiviral immune response in mice devoid of immunoproteasome activity.

Michael Basler1, Ulrike Beck, Christopher J Kirk, Marcus Groettrup.   

Abstract

The replacement of the catalytically active proteasome subunits β1, β2, and β5 by the immunoproteasome subunits low molecular mass polypeptide (LMP) 2 (β1i), multicatalytic endopeptidase complex-like-1 (MECL-1) (β2i), and LMP7 (β5i) is required for the production of numerous class I ligands. Hitherto, investigation of the immunoproteasome was confined to the analysis of mice deficient for one or two immunosubunits. In this study, we characterized LMP2(-/-)/MECL-1(-/-) double-deficient mice and used the well-defined LMP7-selective inhibitor ONX 0914 in these mice to generate mice lacking the activity of all immunoproteasome subunits. LMP2(-/-)/MECL-1(-/-) double-deficient mice had strongly reduced numbers of CD8(+) T cells in the spleen. Nevertheless, infection with the lymphocytic choriomeningits virus induced a normal cytotoxic T cell response in these mice, although the T cell response to several class I epitopes was altered. Treatment of LMP2(-/-)/MECL-1(-/-) double-deficient mice with the LMP7-selective inhibitor ONX 0914 elicited a strong CTL response in lymphocytic choriomeningitis virus-infected mice. Thereby, the T(CD8+) response to nucleoprotein 205-212, which is barely detectable in LMP2(-/-)/MECL-1(-/-) double-deficient mice, could be reverted to normal levels by LMP7 inhibition. Additional experiments could demonstrate that the increased CTL response to the nucleoprotein 205-212 in mice lacking functional immunoproteasome is due to an altered class I presentation of this epitope. Taken together, to our knowledge, this is the first study investigating viral infection in mice lacking activity of all three immunoproteasome subunits.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22013127     DOI: 10.4049/jimmunol.1101064

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Immunoproteasomes: structure, function, and antigen presentation.

Authors:  Deborah A Ferrington; Dale S Gregerson
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

2.  Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.

Authors:  Michael Basler; Elmer Maurits; Gerjan de Bruin; Julia Koerner; Herman S Overkleeft; Marcus Groettrup
Journal:  Br J Pharmacol       Date:  2017-11-29       Impact factor: 8.739

3.  Immunoproteasome Subunits Are Required for CD8+ T Cell Function and Host Resistance to Brucella abortus Infection in Mice.

Authors:  Gabriela Guimarães; Marco Túlio R Gomes; Priscila C Campos; Fabio V Marinho; Natan R G de Assis; Tatiana N Silveira; Sergio C Oliveira
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

4.  Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.

Authors:  Michael Basler; Michelle M Lindstrom; Jacob J LaStant; J Michael Bradshaw; Timothy D Owens; Christian Schmidt; Elmer Maurits; Christopher Tsu; Herman S Overkleeft; Christopher J Kirk; Claire L Langrish; Marcus Groettrup
Journal:  EMBO Rep       Date:  2018-10-02       Impact factor: 8.807

5.  Interferon-dependent immunoproteasome activity during mouse adenovirus type 1 infection.

Authors:  Mary K McCarthy; Danielle H Malitz; Caitlyn T Molloy; Megan C Procario; Kaitlyn E Greiner; Luna Zhang; Ping Wang; Sharlene M Day; Saul R Powell; Jason B Weinberg
Journal:  Virology       Date:  2016-08-22       Impact factor: 3.616

Review 6.  Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.

Authors:  Michael Basler; Marcus Groettrup
Journal:  Genes Immun       Date:  2020-08-25       Impact factor: 2.676

Review 7.  Subunit specific inhibitors of proteasomes and their potential for immunomodulation.

Authors:  Alexei F Kisselev; Marcus Groettrup
Journal:  Curr Opin Chem Biol       Date:  2014-09-15       Impact factor: 8.822

8.  PR-957 mediates neuroprotection by inhibiting Th17 differentiation and modulating cytokine production in a mouse model of ischaemic stroke.

Authors:  Y Guo; X Chen; D Li; H Liu; Y Ding; R Han; Y Shi; X Ma
Journal:  Clin Exp Immunol       Date:  2018-04-23       Impact factor: 4.330

Review 9.  On the role of the immunoproteasome in transplant rejection.

Authors:  Michael Basler; Jun Li; Marcus Groettrup
Journal:  Immunogenetics       Date:  2018-09-15       Impact factor: 2.846

10.  Age-Dependent Effects of Immunoproteasome Deficiency on Mouse Adenovirus Type 1 Pathogenesis.

Authors:  Adithya Chandrasekaran; Laura J Adkins; Harrison M Seltzer; Krittika Pant; Stephen T Tryban; Caitlyn T Molloy; Jason B Weinberg
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.